Latest Breaking News On - புற்றுநோய்கள் சிம்போசியம் - Page 9 : comparemela.com

Janssen Pharmaceutica NV: Janssen Announces Treatment with ERLEADA?(apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Janssen Pharmaceutica NV: Janssen Announces Treatment with ERLEADA?(apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer FOR EMEA PHARMACEUTICAL TRADE AND MEDICAL MEDIA ONLY NOT FOR DISTRIBUTION IN BENELUX, SWEDEN AND ITALY Janssen Pharmaceutica NV (Janssen) announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of apalutamide plus androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) when compared to placebo plus ADT. 1 Results will be featured in an oral presentation at the American Society of Clinical Oncology s Genitourinary (ASCO GU) Cancers Symposium, taking place virtually February 11-13, 2021 (Abstract #11; Rapid Abstract Session: Prostate Cancer, February 11 9:30 PM-10:15 PM CET).

United statesAlexandra nisipeanuNoah reymondJennifer mcintyreChristopher deloreficeAxel merseburgerAsia pacificAmerican society of clinical oncologyMonitoring committeeJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonExchange commissionCompanies of johnsonEuropean medicines agencyAmerican societyClinical oncology

Janssen Announces Treatment with ERLEADA® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer

Share this article Share this article RARITAN, N.J., Feb. 8, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of the addition of ERLEADA ® (apalutamide) to androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC), regardless of extent of disease, when compared to placebo plus ADT. 1 Results will be featured in an oral presentation at the American Society of Clinical Oncology s Genitourinary (ASCO GU) Cancers Symposium, taking place virtually February 11-13, 2021 (Abstract #11; Rapid Abstract Session: Prostate Cancer, February 11, 3:30 PM-4:15 PM EST).

United statesJennifer mcintyreChristopher deloreficeObrian kenneyAsia pacificAmerican society of clinical oncologyNational comprehensive cancer network incMonitoring committeeDrug administrationAmerican urological associationJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonLaboratory abnormalitiesExchange commissionProstate cancer panel

Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination

Share this article Share this article RARITAN, N.J., Feb. 8, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA ® and ZYTIGA ® plus prednisone (control arm). 1 Results will be featured in an oral presentation at the American Society of Clinical Oncology s Genitourinary (ASCO GU) Cancers Symposium, taking place virtually February 11-13, 2021 (Abstract #9; Oral Abstract Session: Prostate Cancer, February 11, 12:45 PM-2:00 PM EST).

United statesJennifer mcintyreChristopher deloreficeObrian kenneyNone of the janssen pharmaceutical companiesNational comprehensive cancer network incWorld health organizationDrug administrationAmerican urological associationJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonLaboratory abnormalitiesExchange commissionProstate cancer panelCompanies of johnson

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), Abeona Therapeutics Inc (NASDAQ:ABEO) - The Week Ahead In Biotech (Feb 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), Abeona Therapeutics Inc (NASDAQ:ABEO) - The Week Ahead In Biotech (Feb 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

United statesPacific biosciencesClovis oncology incSurmodics incJazz pharmaceuticalsCalifornia incInternational blood marrow transplant researchMerck co incExelixis incEquillium incBioventus incAvrobio incIncyte corporationProtalix biotherapeutics incDenali therapeutics incRegeneron pharmaceuticals inc

The Week Ahead In Biotech (Feb 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight

The Week Ahead In Biotech (Feb 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.